Pacira Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
Pacira Biosciences, Inc. (PCRX) filed this Current Report on Form 8-K on August 4, 2026. The filing serves to announce the company's financial results for the second quarter ended June 30, 2026. The full details of these results are contained in the press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached Exhibit 99.1 (Earnings Press Release), which is not included in the source text provided for this summary.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the full text of the press release in Exhibit 99.1 for comparative financial analysis.
Guidance, Outlook, and Risks
This Form 8-K does not include specific guidance, outlook, management commentary, or risk factors within the body of the report. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference except as expressly set forth.
Key Facts for Investor Verification
- Verify the specific revenue and net income figures for the quarter ended June 30, 2026, in the attached Exhibit 99.1.
- Review the full press release for any updated forward-looking guidance or strategic initiatives.
- Confirm the status of the company's cash position and debt obligations as detailed in the earnings release.
- Note that the financial data in this filing is furnished but not "filed" under Section 18 of the Exchange Act.